PhysioSonics Inc., a Seattle-based developer of noninvasive neurologic products, has held a $4 million first close on its Series A round, from Johnson & Johnson Development Corp.
PhysioSonics, Inc., an innovator of noninvasive neurologic products, announced today the first close of its Series A financing with an investment from Johnson & Johnson Development Corporation (JJDC). This funding brings the total Series A raised to over $4.0 Million. The company will use these funds for commercialization of their first product. “We are excited to work with JJDC and the Johnson & Johnson companies as we commercialize our technology,” says Brad Harlow, President & CEO of PhysioSonics
Additionally, PhysioSonics partnered with Verasonics, a
About PhysioSonics, Incorporated
PhysioSonics, formerly known as Allez PhysiOnix, is a privately held company, founded in 2000 with technology developed at the
Verasonics is a privately held company located in
Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson (NYSE:JNJ). JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies.